Synchrony Bank review (2025): Earn more on your savings with this top-rated online bank
Synchrony's high-yield savings account ranks as one of our top 10 high-yield savings accounts available today. It's a free online savings account with no minimum balance requirements or monthly fees. This account currently boasts an annual percentage yield (APY) of 4.00% and offers an optional ATM card for easy access to your funds. Synchrony Bank will refund domestic ATM fees charged by other financial institutions, up to $5.00 per statement cycle.
Synchrony's money market account, which ranks among our 10 best high-yield money market accounts, is also free to open with no minimum deposit or minimum balance required. This account currently offers 2.00% APY and no monthly fees. An IRA money market account is also available for your retirement savings.
Synchrony Bank's CDs come in several term lengths, ranging from three months to five years. CDs do not have a minimum balance requirement and offer rates as high as 4.25% APY. Synchrony also offers IRA CD accounts for customers who are focused on saving for retirement.
Synchrony currently offers a range of cash back and retail credit cards, as well as financing through popular merchants such as Rooms To Go, Sam's Club, JCPenney, Belk, QVC, Lowes, and more. It also offers Synchrony Pay, a buy now, pay later (BNPL) service.This embedded content is not available in your region.
If you're considering banking with Synchrony, here are some of the fees you should be aware of:
Here's a closer look at some of the major pros and cons of banking with Synchrony:
Pros:
Competitive interest rates on deposit products: Synchrony's bank accounts come with rates as high as 4.25% — well above national averages.
No minimum opening deposit: Synchrony does not require a minimum deposit amount to open an account. It also doesn't require customers to maintain a minimum balance.
Cons:
Does not offer a checking account: Synchrony does not currently offer a checking account, only savings products and credit cards.
Does not have any physical branches: Synchrony is an online-only bank with no physical branches for customers to visit.
Synchrony Bank representatives are available via live chat and telephone Monday through Friday from 8 a.m. to 10 p.m. ET and weekends between 8 a.m. and 5 p.m. ET. There is also a 24/7 automated telephone service. You can also contact the bank via secure message and mail.
Synchrony customers can bank directly from their mobile phones by downloading the Synchrony mobile app, which is available on the App Store and Google Play and has an average rating of 4.8 and 4.6 stars, respectively.
On the app, customers can transfer money between accounts, check balances, deposit checks, chat with customer support, and more.
Synchrony focuses on a few key areas to make the greatest impact in the communities it serves. This includes volunteering time and skills to serve communities in need, supporting nonprofit organizations that benefit small businesses, donating to charitable organizations, and closing the financial knowledge gap through its 'Education as an Equalizer' initiative.
Through this initiative, Synchrony has committed to investing $50 million into the program to fund grants to academic institutions, nonprofits, and skills credentialing organizations.
Synchrony has also worked to reduce its consumption, lower emissions, and waste, and improve efficiency through the implementation of more energy-efficient buildings, reducing waste from paper, food, electronics, and more.
Yes, Synchrony is a Fortune 500 company with a history that spans more than 80 years.
While Synchrony Bank operates primarily online, it does have one branch location in each of the following states: Georgia, Kansas, New Jersey, North Carolina, and Utah.
Formerly known as GE Capital Retail Bank, Synchrony Bank is owned by Synchrony Financial, based in Stamford, Connecticut.
Yes, Synchrony Bank is an FDIC-insured bank. All of the accounts offered by Synchrony are insured up to $250,000 per depositor, per insured bank, for each ownership category.
Synchrony Bank's routing number is 021213591.
No. Synchrony Bank currently offers savings and credit card products. It does not offer a checking account.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
5 hours ago
- Miami Herald
Jean Chatzky sends strong message on 401(k)s, IRAs
Many Americans planning for retirement are often encouraged to start by contributing to both a company-sponsored 401(k) plan and an Individual Retirement Account (IRA) as major parts of their financial strategy. Former NBC Today Show financial editor Jean Chatzky offers a key data point on U.S. household retirement savings progress and explains some important things to know about the 401(k) and IRA challenge facing Americans. Don't miss the move: Subscribe to TheStreet's free daily newsletter Individuals should consider placing a high priority on contributing to an employer-sponsored 401(k) - especially when matching contributions from the company are available, the HerMoney founder explained. With automatic deductions taken directly from paychecks, Chatzky clarified, this approach requires minimal effort and decision-making, offering a streamlined and effective path to retirement savings. In Chatzky's July 22 HerMoney email newsletter, she explained why one important number regarding IRAs is 44%. "That's the percentage of U.S. households saving for retirement through IRAs – accounts that hold over $16.2 trillion and make up 38% of all U.S. retirement wealth," Chatzky wrote, citing an Investment Company Institute report. "No IRA, you say?" she asked. "For many women, these accounts are key to closing the retirement savings gap." Jean Chatzky describes gap annuities as a financial tool crafted to bridge the income divide that can occur between leaving the workforce and the start of other retirement benefits, such as Social Security or a pension. Gap annuities can also help delay the time when a person would otherwise make withdrawals from their 401(k) plans and IRAs. These short-term annuities - generally lasting between three and ten years - are typically funded through a lump sum or a series of payments. In return, they offer reliable income over a defined period. Chatzky likens them to a substitute paycheck, providing a steady cash flow for retirees - or anyone experiencing a temporary break in earnings. More on personal finance: Dave Ramsey warns Americans on Social SecurityJean Chatzky sends strong message on major 401(k) changesFinance expert has blunt words for car buyers Who gap annuities are good for In the HerMoney newsletter, Chatzky describes the financial situations that make sense for when people should consider gap annuities. Early retirees who want to wait to start collecting Social Security in order to maximize their monthly who are waiting on a pension or another delayed income who need income before their required minimum distributions (RMDs) begin at age 73 or 75, depending on your birth year. Retirees without pensions who want to turn part of their retirement nest egg into a steady income stream – basically creating their own DIY pension. "Unlike lifetime annuities, gap annuities are time-limited, making them more flexible and often less expensive," Chatzky wrote. "As with all financial products, make sure you read the fine print - watch out for fees, surrender charges and whether or not the income keeps up with inflation," she added. Chatzky has explained her approach to investing in retirement savings accounts, even in times of volatility in the market. "I'm always buying," she said. "I think I'm very much the typical retirement investor. I put money into the markets in my 401(k) and other retirement accounts and brokerage accounts on a regular basis in a very methodical way." Chatzky has emphasized the fact that she typically avoids investing in individual stocks, preferring a more diversified approach through mutual funds. While she views stock-picking as an occasional source of enjoyment, her main strategy involves staying the course with long-term investments. Chatzky also outlined another method she believes can support investors during market downturns, aimed at helping people maintain their financial footing when stock values dip. Related: Jean Chatzky warns Americans on a slick Roth IRA retirement move "You should always try to have enough in bonds and cash that you could prevent yourself from having to sell when stocks are really down," Chatzky has said. "Other than that, I think we really can't control these things." The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Yahoo
8 hours ago
- Yahoo
Wall Street Bets on U.S. Graphite as China Faces 160% Tariffs
Combined with existing tariffs, the 93.5% preliminary anti-dumping tariffs the U.S. Commerce Department announced this week on anode-grade graphite imported from China, targeting nearly $350 million in goods, promises to deal a major blow to battery producers. It would bring the tariffs to 160% on the notion that Chinese graphite is being sold in the U.S. below fair market value. And it gets worse than that for some Chinese producers. China's Huzhou Kaijin New Energy Technology and Shanghai Shaosheng Knitted Sweat, specifically, will face even higher duties exceeding 700%. The final determinations will be announced by December 5, 2025. The latest tariffs stem from a petition filed in December by the American Active Anode Material Producers for alleged violations of anti-dumping regulations, and the impact on the American EV battery supply chain will likely be significant. The United States imported ~180,000 metric tons of graphite in 2023, with two-thirds coming from China. According to a recent report by the International Energy Agency (IEA), the U.S. graphite supply chain remains highly vulnerable to supply disruptions, with the energy agency calling for urgent diversification efforts. The IEA has projected that graphite will remain the most widely used anode material in lithium-ion batteries over the next five years, with silicon expected to gradually gain ground after latest tariffs on graphite are expected to escalate tensions between the two countries, with the U.S. EV sector already feeling the heat after Beijing imposed export restrictions on certain critical minerals and battery technologies. In December 2024, China implemented export restrictions on several critical minerals, including gallium, germanium, antimony, and graphite, primarily targeting the U.S. This action is seen as a response to increased tariffs and trade tensions with the US. The ban has significant implications for various industries globally, particularly those reliant on semiconductors, electronics, and renewable energy technologies. The cost implications of the tariffs will also be significant. According to Sam Adham, Head of Battery Materials at CRU Group, battery costs could increase by roughly $7/kWh once the tariffs take effect, effectively cutting ~20% of tax credits under the U.S. Inflation Reduction Act (IRA). 'I think this is going to change behaviors and sourcing strategies of battery manufacturers in the United States,' Michael O'Kronley, chief executive officer at Novonix, told Bloomberg. 'The cost of graphite imported from China is going to go up. This ruling essentially is going to accelerate some of those discussions we have with manufacturers.' That's the reason why major EV players such as Tesla Inc. (NASDAQ:TSLA) and Panasonic have lobbied hard against the tariffs, citing an insufficient domestic supply chain to meet their quality and volume needs. Back in May, analysis from the International Council on Clean Transportation projected that U.S. battery production would decline by ~75% by 2030 to 250 GWh and EV sales by 40% under the Trump administration. According to the report, Trump's 'Big Beautiful Bill', which he signed into law earlier this month, could eliminate 130,000 potential jobs in the EV sector by 2030, the majority being in battery manufacturing. Previously, companies had announced a total of 128 U.S. facilities for battery manufacturing in the country thanks to generous credits under the 2022 IRA, with more than half yet to begin construction. Not surprisingly, TSLA took a hit, falling 3% after the tariffs were announced, while stocks of non-Chinese graphite producers soared: Shares of Canada's Northern Graphite Corporation (OTCQB:NGPHF) have doubled; Australian graphite miner, Syrah Resources Ltd. (OTCPK:SYAAF), have surged nearly 40%, Novonix Ltd. (OTCPK:NVNXF), an Australian-listed graphite producer with a plant in Chattanooga, Tennessee, jumped 21%, Canada's Nouveau Monde Graphite (NYSE:NMG) gained 23% while South Korea's POSCO Holdings Inc. (NYSE:PKX) gained 5%. Interestingly, Northern Graphite is one of the companies that lobbied for the tariffs on Chinese graphite. Northern Graphite engages in the development and production of graphite and other minerals in Canada and Namibia. Meanwhile, Wall Street is bullish about the U.S. graphite sector, saying the tariffs will encourage companies like Tesla to buy their graphite from U.S. producers. 'The U.S. is likely to be promoting the development of its own graphite industry by forcing domestic battery makers to switch suppliers,' said Eugene Hsiao, head of China equity strategy at Macquarie Capital, as reported by Bloomberg. 'Thus upstream suppliers of Chinese graphite anodes are more likely to be impacted.' That shift is expected to hit Chinese suppliers hard, particularly those who have long dominated the synthetic and natural graphite anode markets with low-cost exports. According to trade data, over 65% of U.S. graphite imports in 2023 originated from China, with companies like BTR New Energy, Shanghai Shanshan, and Huzhou Kaijin heavily exposed. With anti-dumping duties pushing effective tariff rates to as high as 160% (and over 700% for certain producers) the cost advantage that underpinned Chinese market share is rapidly eroding. Analysts expect many of these upstream firms to lose access to U.S. buyers unless they shift production offshore or absorb significant margin compression. Beijing's December 2024 export restrictions on graphite further complicate the picture, heightening uncertainty for Chinese exporters already navigating increased geopolitical and cost pressures. By Alex Kimani for More Top Reads From this article on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Hamilton Spectator
10 hours ago
- Hamilton Spectator
Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences
VICTORIA, British Columbia, July 22, 2025 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. ('Eupraxia' or the 'Company') (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the Company's management team will present and participate at the following upcoming investor conferences: Canaccord Growth 45th Annual Growth Conference Date: August 12 - 14, 2025 Presentation date & time: August 13, 2025, 9:30am ET Location: Boston, MA Citi Biopharma Back to School Conference Date: September 2-3, 2025 Location: Boston, MA Cantor Global Healthcare Conference Date: September 3-5, 2025 Presentation date & time: September 5, 2025, 9:10am ET Location: New York, NY H.C. Wainwright 27th Annual Global Investment Conference Date: September 8-10, 2025 Location: New York, NY About Eupraxia Pharmaceuticals Inc. Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians are wanting to treat. We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the DiffuSphere™ technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia's DiffuSphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease and other critical disease areas. Eupraxia's EP-104GI is currently in a Phase 1b/2 trial, the RESOLVE trial, for the treatment of EoE. EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also recently completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. The trial met its primary endpoint and three of the four secondary endpoints. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the Company's website at: . Notice Regarding Forward-looking Statements and Information This news release includes forward-looking statements and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking information can be identified by the use of words such as 'plans', 'is expected', 'expects', 'suggests', 'scheduled', 'intends', 'contemplates', 'anticipates', 'believes', 'proposes', 'potential' or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results 'may', 'could', 'would', 'might' or 'will' be taken, occur or be achieved. Forward-looking statements in this news release include statements regarding the expected enrollment and number of sites for the Phase 2b portion of the RESOLVE study; the expected parameters of the RESOLVE study; the availability of topline data and release of additional long-term data with higher doses and timing thereof; the Company's product candidates, including their expected benefits to patients with respect to safety, tolerability, efficacy and duration; the expectations around proceeding to clinical trials for the Company's product candidates; the results gathered from studies and trials of Eupraxia's product candidates; the potential for the Company's technology to impact the drug delivery process; potential market opportunity for the Company's product candidates; and potential pipeline indications. Such statements and information are based on the current expectations of Eupraxia's management, and are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Company's ability to obtain positive results from the Company's research and development activities, including clinical trials; and the Company's ability to protect patents and proprietary rights. Although Eupraxia's management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Company's limited operating history; the Company's novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product candidates or technology from third parties, the Company could lose license rights that are important to its business; the Company's current license agreement may not provide an adequate remedy for its breach by the licensor; the Company's technology may not be successful for its intended use; the Company's future technology will require regulatory approval, which is costly and the Company may not be able to obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the Company's clinical trials may fail to demonstrate adequately the safety and efficacy of its product candidates at any stage of clinical development; the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the Company completely relies on third parties to provide supplies and inputs required for its product candidates and services; the potential impact of tariffs on the cost of the Company's active pharmaceutical ingredients and clinical supplies of EP-104IAR and EP-104GI; the Company relies on external contract research organizations to provide clinical and non-clinical research services; the Company may not be able to successfully execute its business strategy; the Company will require additional financing, which may not be available; any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company's ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Company's operations; the Company's restatement of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on the Company's common share price; and other risks and uncertainties described in more detail in Eupraxia's public filings on SEDAR+ ( and EDGAR ( Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise. For investor and media inquiries, please contact: Danielle Egan, Eupraxia Pharmaceuticals Inc. 778.401.3302 degan@ or Kevin Gardner, on behalf of: Eupraxia Pharmaceuticals Inc. 617.283.2856 kgardner@ SOURCE Eupraxia Pharmaceuticals Inc.
